title: Remifentanil attenuates lipopolysaccharide-induced acute lung injury by downregulating the NF-κB signaling pathway.
abstract: Remifentanil significantly represses cell immune responses and influences neutrophil migration through endothelial cell monolayers. The present study determines the beneficial effects of remifentanil and the mechanisms by which it attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI). Rats were intratracheally instilled with 2 mg/kg LPS to induce ALI. Results showed that remifentanil could resolve lung injury, as evidenced by remarkable decreases in lung edema (wet-to-dry weight ratio), neutrophil infiltration (myeloperoxidase activity), and pulmonary permeability [total number of cells and protein concentrations in bronchoalveolar lavage fluid (BALF)]. Remifentanil also attenuated the concentrations of proinflammatory cytokines tumor necrosis factor alpha, interleukin-1β, and interleukin-6 in BALF, as well as effectively repressed the activation of nuclear factor-kappaB (NF-κB), which has been associated with the inhibition of IκBα degradation.These results suggest that remifentanil may be a suitable treatment for LPS-induced ALI. Remifentanil exerts beneficial effects on the inhibition of proinflammatory cytokine production by downregulating the NF-κB pathway.
authors.affiliation: Department of Anesthesia, Critical Care Medicine & Emergency Medicine Center, Zhongnan Hospital, Wuhan University, Wuhan, 430071, Hubei Province, People's Republic of China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
authors.forename: Zhaohui
authors.initials: Z
authors.lastname: Du
authors.forename: Qing
authors.initials: Q
authors.lastname: Zhou
authors.forename: Yanlin
authors.initials: Y
authors.lastname: Wang
authors.forename: Jianguo
authors.initials: J
authors.lastname: Li
mesh_terms: D055371:Acute Lung Injury / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D015536:Down-Regulation / Q000187:drug effects* / Q000502:physiology; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000633:toxicity*; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077208:Remifentanil; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology
chemical_list: D008070:Lipopolysaccharides; D016328:NF-kappa B; D010880:Piperidines; D000077208:Remifentanil
references.citation: Am J Physiol Lung Cell Mol Physiol. 2008 Sep;295(3):L379-99
references.pmid: 18621912
references.citation: Cytokine Growth Factor Rev. 2003 Dec;14(6):523-35
references.pmid: 14563354
references.citation: Arch Pharm Res. 2008 Feb;31(2):133-41
references.pmid: 18365680
references.citation: J Immunol. 1997 Oct 15;159(8):3976-83
references.pmid: 9378986
references.citation: Tohoku J Exp Med. 2010 Sep;222(1):7-13
references.pmid: 20805679
references.citation: Acta Anaesthesiol Scand. 2000 Nov;44(10):1232-7
references.pmid: 11065203
references.citation: Am J Respir Cell Mol Biol. 2005 Oct;33(4):319-27
references.pmid: 16172252
references.citation: Crit Care Med. 1996 Aug;24(8):1285-92
references.pmid: 8706481
references.citation: J Immunol. 1996 Aug 15;157(4):1630-7
references.pmid: 8759749
references.citation: Microvasc Res. 2009 Jan;77(1):8-12
references.pmid: 18929580
references.citation: Shock. 2008 Oct;30(4):468-72
references.pmid: 18391858
references.citation: Am J Physiol Lung Cell Mol Physiol. 2001 Nov;281(5):L1037-50
references.pmid: 11597894
references.citation: Chin Med J (Engl). 2011 Apr;124(7):1069-74
references.pmid: 21542970
references.citation: Int Immunopharmacol. 2001 Apr;1(4):713-9
references.pmid: 11357883
references.citation: Intensive Crit Care Nurs. 2002 Dec;18(6):355-7
references.pmid: 12526873
references.citation: J Korean Med Sci. 2004 Feb;19(1):55-61
references.pmid: 14966342
references.citation: N Engl J Med. 2000 May 4;342(18):1334-49
references.pmid: 10793167
references.citation: Am Rev Respir Dis. 1986 May;133(5):913-27
references.pmid: 3085564
references.citation: Am J Physiol Lung Cell Mol Physiol. 2000 Dec;279(6):L1137-45
references.pmid: 11076804
references.citation: Nucleic Acids Res. 1991 May 11;19(9):2499
references.pmid: 2041787
references.citation: Anaesth Intensive Care. 2008 Jan;36(1):74-8
references.pmid: 18326136
references.citation: Mol Biol Rep. 2010 Jul;37(6):2803-8
references.pmid: 19757155
references.citation: Leg Med (Tokyo). 2003 Mar;5 Suppl 1:S45-57
references.pmid: 12935551
references.citation: Eur J Pharmacol. 2010 Sep 10;642(1-3):146-53
references.pmid: 20519138
references.citation: J Clin Invest. 2006 Sep;116(9):2316-9
references.pmid: 16955131
references.citation: Anal Biochem. 1972 Aug;48(2):422-7
references.pmid: 4115981